Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Abdelkader Seroutou

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
BMC Medical Research Methodology|April 15, 2021
Phase I dose-escalation oncology trials with sequential multiple schedulesBurak Kürsad Günhan, Sebastian Weber, Abdelkader Seroutou, et al.
British Journal of Cancer|May 4, 2021
Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumoursJordi Rodon, Guillem Argilés, Roisin M Connolly, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2017
Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic <i>BRAF</i>-Mutant MelanomaJean-Pierre Delord, Caroline Robert, Marta Nyakas, et al.
BMC Cancer|September 14, 2017
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancerKerry Lynn Reynolds, Philippe L Bedard, Se-Hoon Lee, et al.
Nature Medicine|December 1, 2022
Angiopoietin-like 3-derivative LNA043 for cartilage regeneration in osteoarthritis: a randomized phase 1 trialNicole Gerwin, Celeste Scotti, Christine Halleux, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
BMC Medical Research Methodology|April 15, 2021
Phase I dose-escalation oncology trials with sequential multiple schedulesBurak Kürsad Günhan, Sebastian Weber, Abdelkader Seroutou, et al.
British Journal of Cancer|May 4, 2021
Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumoursJordi Rodon, Guillem Argilés, Roisin M Connolly, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2017
Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic <i>BRAF</i>-Mutant MelanomaJean-Pierre Delord, Caroline Robert, Marta Nyakas, et al.
BMC Cancer|September 14, 2017
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancerKerry Lynn Reynolds, Philippe L Bedard, Se-Hoon Lee, et al.
Nature Medicine|December 1, 2022
Angiopoietin-like 3-derivative LNA043 for cartilage regeneration in osteoarthritis: a randomized phase 1 trialNicole Gerwin, Celeste Scotti, Christine Halleux, et al.
Pageof 1